Am J Cardiovasc Drugs. 2020 Aug 1. doi: 10.1007/s40256-020-00429-7. Online ahead of print.
ABSTRACT
Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.
PMID:32737841 | DOI:10.1007/s40256-020-00429-7